Celldex Therapeutics Prices $300M Public Offering to Fund Barzolvolimab Commercialization and Pipeline

summarizeSummary

Celldex Therapeutics has priced an underwritten public offering of 10.345 million shares at $29.00 per share, raising approximately $300 million to advance its lead drug candidate barzolvolimab and other pipeline programs.

check_boxKey Events

• Public Offering Priced

  Celldex Therapeutics priced an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share, finalizing the terms of the offering initiated on April 1, 2026.

• Significant Capital Raise

  The offering is expected to generate approximately $300 million in gross proceeds, or $281.8 million net of underwriting discounts and commissions.

• Funding Strategic Initiatives

  Proceeds will fund commercial readiness and launch of barzolvolimab, ongoing clinical and preclinical development, and expansion of the bispecific antibody platform.

• Share Dilution

  The offering will increase outstanding shares by approximately 15.5% (excluding the underwriters' option), leading to immediate dilution for new investors of $18.83 per share.

auto_awesomeAnalysis

This 424B5 filing finalizes the terms and pricing of the underwritten public offering previously announced on April 1, 2026. The offering of 10,345,000 shares, priced at $29.00 per share, will generate approximately $300 million in gross proceeds, or $281.8 million net of underwriting discounts and commissions. This represents a substantial capital infusion for Celldex, providing critical funding for commercial readiness and launch of its lead drug candidate barzolvolimab, continued clinical and preclinical development, and expansion of its bispecific antibody platform. The offering will result in approximately 15.5% dilution to existing shareholders, with new investors experiencing an immediate dilution of $18.83 per share. This financing follows recent positive Phase 2 data for barzolvolimab, positioning the company to capitalize on its clinical progress and strengthen its financial runway.